Q-omics provides the consensus-scored ANK3-DT profile across patient tissues and cancer cell-line models. ANK3-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ANK3-DT is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ANK3-DT RNA expression shows 11,175 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where ANK3-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANK3-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANK3-DT survival associations across molecular data types. ANK3-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANK3-DT RNA expression–survival associations across cancer types. High ANK3-DT expression shows unfavorable associations in LGG, but favorable associations in BRCA, KIRC, OV, BLCA and COAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ANK3-DT RNA expression.
This table summarizes ANK3-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANK3-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANK3-DT shows lower tumor expression in KIRC, KIRP, KICH and THCA and higher tumor expression in BLCA and BRCA. The KIRC box plot shows higher ANK3-DT RNA expression in normal versus tumor tissue (log2 FC = −1.512, t-test p < 0.001).
This table shows molecular features associated with ANK3-DT in patient tissues and cancer cell lines. In patient samples, ANK3-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
